Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases.
Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Aharoni Golan M, Shachar E, Ben-Horin S, Maharshak N, Mor M, Ben Zvi H, Eliakim R, Barkan R, Sharar-Fischler T, Goren S, Krugliak N, Pichinuk E, Mor M, Werbner M, Alter J, Abu-Taha H, Kaboub K, Dessau M, Gal-Tanamy M, Cohen D, Freund NT, Dotan I, On Behalf Of The Responses To Covid-Vaccine Israeli Ibd. Rabinowitz KM, et al. Vaccines (Basel). 2022 Jul 26;10(8):1186. doi: 10.3390/vaccines10081186. Vaccines (Basel). 2022. PMID: 35893835 Free PMC article.
Probiotics and prebiotics in Crohn's disease therapies.
Lichtenstein L, Avni-Biron I, Ben-Bassat O. Lichtenstein L, et al. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):81-8. doi: 10.1016/j.bpg.2016.02.002. Epub 2016 Feb 9. Best Pract Res Clin Gastroenterol. 2016. PMID: 27048899 Review.
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039. Inflamm Bowel Dis. 2017. PMID: 28178003
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Kopylov U, et al. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155. Inflamm Bowel Dis. 2018. PMID: 29788318
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, Ungar B, Schwartz D, Zittan E, Openhaim M, Yanai H, Maharshak N, Bar Gil Shitrit A, Naftali T, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Dig Liver Dis. 2019 Jan;51(1):68-74. doi: 10.1016/j.dld.2018.07.040. Epub 2018 Aug 10. Dig Liver Dis. 2019. PMID: 30172649 Clinical Trial.
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A, Ben-Ya'acov A, Siterman M, Waterman M, Hirsh A, Schwartz D, Zittan E, Adler Y, Koslowsky B, Avni-Biron I, Chowers Y, Ron Y, Israeli E, Ungar B, Yanai H, Maharshak N, Ben-Horin S, Eliakim R, Dotan I, Goldin E, Kopylov U. Bar-Gil Shitrit A, et al. United European Gastroenterol J. 2020 May;8(4):418-424. doi: 10.1177/2050640620902956. Epub 2020 Jan 24. United European Gastroenterol J. 2020. PMID: 32213026 Free PMC article.
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, Leibovitzh H, Banai Eran H, Aharoni Golan M, Rabinowitz K, Ziv Baran T, Lavie I, Yadgar K, Zonensain K, Kopylov U, Ben Horin S, Eliakim R, Waterman M, Chowers Y, Ben-Shachar S, Dotan I; Israeli IBD Research Nucleus. Yanai H, et al. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1564-1572.e5. doi: 10.1016/j.cgh.2020.06.069. Epub 2020 Jul 3. Clin Gastroenterol Hepatol. 2021. PMID: 32629126
36 results